Anti-TNF-α therapy for patients with sepsis: a systematic meta-analysis

PaORillo, 1990, Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy, Ann Intern Med, 113, 227, 10.7326/0003-4819-113-3-227

Angus, 2001, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care, Crit Care Med, 29, 1303, 10.1097/00003246-200107000-00002

Sharma, 2006, Treatment options for severe sepsis and septic shock, Expert Rev Anti Infect Ther, 4, 395, 10.1586/14787210.4.3.395

Nawroth, 1986, Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin, J Exp Med, 163, 1363, 10.1084/jem.163.6.1363

Spooner, 1992, The role of tumor necrosis factor in sepsis, Clin Immunol Immunopathol, 62, S11, 10.1016/0090-1229(92)90036-N

Dellinger, 2008, Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, Crit Care Med, 36, 296, 10.1097/01.CCM.0000298158.12101.41

Robinson, 2002, Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed, Int J Epidemiol, 31, 150, 10.1093/ije/31.1.150

Higgins, 2011, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928

Abraham, 1995, Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group, JAMA, 273, 934, 10.1001/jama.1995.03520360048038

Abraham, 1997, p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group, JAMA, 277, 1531, 10.1001/jama.1997.03540430043031

Abraham, 1998, Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group, Lancet, 351, 929, 10.1016/S0140-6736(05)60602-2

Abraham, 2001, Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study, Crit Care Med, 29, 2081, 10.1097/00003246-200111000-00007

Butty, 2003, Geneva Sepsis Network. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis, Eur Cytokine Netw, 14, 15

Clark, 1998, Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis - a randomized, clinical trial, Crit Care Med, 26, 1650, 10.1097/00003246-199810000-00016

Cohen, 1996, INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group, Crit Care Med, 24, 1431, 10.1097/00003246-199609000-00002

Dhainaut, 1995, CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group, Crit Care Med, 23, 1461, 10.1097/00003246-199509000-00004

Fisher, 1993, Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group, Crit Care Med, 21, 318, 10.1097/00003246-199303000-00006

Fisher, 1996, Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group, N Engl J Med, 334, 1697, 10.1056/NEJM199606273342603

Gallagher, 2001, A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome, Intensive Care Med, 27, 1169, 10.1007/s001340100973

Morris, 2012, A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock, Crit Care, 16, R31, 10.1186/cc11203

Aikawa, 2013, A phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock, J Infect Chemother, 19, 931, 10.1007/s10156-013-0612-y

Panacek, 2004, Monoclonal anti-TNF: a Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels, Crit Care Med, 32, 2173, 10.1097/01.CCM.0000145229.59014.6C

Reinhart, 2001, Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study, Crit Care Med, 29, 765, 10.1097/00003246-200104000-00015

Reinhart, 1996, Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study, Crit Care Med, 24, 733, 10.1097/00003246-199605000-00003

Rice, 2006, Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis, Crit Care Med, 34, 2271, 10.1097/01.CCM.0000230385.82679.34

Meyer, 2003, Role of TNF-α and cytokines in the physiopathology of rheumatoid arthritis. Therapeutic perspectives, Bull Acad Natl Med, 187, 935

Cammack, 2001, The potential for HIV fusion inhibition, Curr Opin Infect Dis, 14, 13, 10.1097/00001432-200102000-00003

Freeman, 2000, Anti-inflammatory therapies in sepsis and septic shock, Expert Opin Investig Drugs, 9, 1651, 10.1517/13543784.9.7.1651

Eskandari, 1992, Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia, J Immunol, 148, 2724, 10.4049/jimmunol.148.9.2724

Echtenacher, 2001, Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice, Infect Immun, 69, 3550, 10.1128/IAI.69.6.3550-3555.2001

Lorente, 2005, Neutralization of tumor necrosis factor in preclinical models of sepsis, Shock, 24, 107, 10.1097/01.shk.0000191343.21228.78

Begg, 1988, Publication bias: a problem in interpreting medical data, J R Stat Soc A, 151, 419, 10.2307/2982993